Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.60 Insider Own2.30% Shs Outstand333.59M Perf Week-1.04%
Market Cap40.71B Forward P/E- EPS next Y- Insider Trans7.03% Shs Float330.28M Perf Month-13.31%
Income-866.10M PEG- EPS next Q- Inst Own95.80% Short Float1.10% Perf Quarter-11.13%
Sales5.77B P/S7.06 EPS this Y-610.50% Inst Trans-3.08% Short Ratio1.82 Perf Half Y10.32%
Book/sh15.30 P/B7.98 EPS next Y- ROA-3.70% Target Price52.38 Perf Year67.63%
Cash/sh1.80 P/C67.82 EPS next 5Y15.24% ROE-17.90% 52W Range71.61 - 153.10 Perf YTD3.96%
Dividend- P/FCF47.51 EPS past 5Y-33.00% ROI-0.10% 52W High-20.28% Beta0.95
Dividend %- Quick Ratio1.20 Sales past 5Y50.10% Gross Margin67.00% 52W Low70.44% ATR5.83
Employees17200 Current Ratio1.50 Sales Q/Q124.30% Oper. Margin4.60% RSI (14)40.74 Volatility4.74% 5.02%
OptionableYes Debt/Eq3.39 EPS Q/Q227.60% Profit Margin-15.00% Rel Volume0.68 Prev Close121.45
ShortableYes LT Debt/Eq3.35 EarningsMay 05 Payout- Avg Volume1.99M Price122.05
Recom3.00 SMA20-4.15% SMA50-10.42% SMA2006.17% Volume1,358,672 Change0.49%
28-Feb-14Reiterated UBS Buy $141 → $170
28-Feb-14Reiterated RBC Capital Mkts Outperform $151 → $158
27-Feb-14Reiterated Aegis Capital Buy $160 → $180
08-Jan-14Reiterated UBS Buy $125 → $141
08-Jan-14Reiterated Ladenburg Thalmann Buy $123 → $155
08-Jan-14Reiterated FBR Capital Outperform $130 → $153
03-Dec-13Reiterated UBS Buy $115 → $125
01-Nov-13Reiterated Ladenburg Thalmann Buy $127 → $123
30-Oct-13Initiated FBR Capital Outperform $130
07-Oct-13Reiterated CRT Capital Buy $110 → $130
08-Aug-13Reiterated UBS Buy $96 → $115
07-Aug-13Reiterated Aegis Capital Buy $135 → $140
02-Jul-13Reiterated RBC Capital Mkts Outperform $76 → $100
10-Jun-13Upgrade CRT Capital Hold → Buy $100
29-May-13Reiterated Ladenburg Thalmann Buy $84 → $124
29-May-13Reiterated Deutsche Bank Buy $82 → $103
03-May-13Reiterated Deutsche Bank Buy $80 → $82
04-Apr-13Reiterated UBS Buy $83 → $81
04-Apr-13Reiterated RBC Capital Mkts Outperform $80 → $76
21-Mar-13Reiterated Deutsche Bank Buy $77 → $83
15-Apr-14 10:22AM  Albany Molecular Aspires To Grow Revenue Five-Fold In As Many Years at Seeking Alpha
09:32AM  Is This the Time to Buy Pharma Stocks? at Motley Fool
14-Apr-14 05:32PM  Facebook, Walgreen Climb Monday On International News at Investor's Business Daily
11:17AM  Novartis to Shire Said to Weigh Bids for ThromboGenics at Bloomberg
11-Apr-14 04:33PM  Nasdaq Finishes Near 4000 Level In Another Sell-Off at Investor's Business Daily
10-Apr-14 12:58PM  Meet the poster child for momentum stock selloff at CNBC
11:54AM  Next Chapter In The Acorda Story Will Be A Page-Turner at Seeking Alpha
11:54AM  Next Chapter In The Acorda Story Will Be A Page Turner at Seeking Alpha
11:16AM  Ignore Stephen Mandel's top stock picks at MarketWatch
08-Apr-14 06:32PM  Ethical Drug Stocks Are Struggling at Investor's Business Daily
09:55AM  Drug Deals Surge to New High With Mallinckrodt: Real M&A at Bloomberg
09:51AM  4 Ways to Profit From the Aging Population at Motley Fool
07-Apr-14 02:09PM  Sun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy at theflyonthewall.com
09:31AM  Is There Opportunity in the Eye-Care Sector? at Motley Fool
04-Apr-14 06:28PM  IBD 50 Stocks Fade With Market; Some Trip Sell Rules at Investor's Business Daily
01-Apr-14 12:05PM  Top Guru-Held Canadian Stocks Gurufocus
27-Mar-14 05:51PM  Drug, Airline Stocks Top Shortened Weekly Review at Investor's Business Daily
26-Mar-14 04:40PM  Actavis-Valeant Antibiotic Approved Zacks
02:32PM  Will Shire PLC Build Or Buy Its Future? at Motley Fool
11:56AM  Moody's Foresees Junky Valeant Pharmaceuticals Deals at TheStreet
10:30AM  Stocks: Insiders Buy at Regeneron, Valeant, and MDC Partners at Minyanville
10:22AM  3 Canadian Stocks With Russian Exposure at Motley Fool
25-Mar-14 05:00PM  Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% PR Newswire
05:00PM  Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% CNW Group
02:30PM  From Plant to Prescription: 5 Ways Marijuana Made It to the Market Wall St. Cheat Sheet
24-Mar-14 06:58PM  Millennium Management buys a position in Endo International Market Realist
05:56PM  Top Industry Groups Take Big Hits In Market Sell-Off at Investor's Business Daily
05:56PM  Selling Pressure Builds In Leading Growth Stocks, Nasdaq at Investor's Business Daily
02:31PM  3 Reasons the Bears Are Wrong About Valeant Pharmaceuticals at Motley Fool
11:29AM  Interesting VRX Put And Call Options For May 17th at TheStreet
06:26AM  From Plant to Prescription: 5 Ways Marijuana Made It to the Market at Wall St. Cheat Sheet
23-Mar-14 06:26PM  From Plant to Prescription: 5 Ways Marijuana Made It to the Market at Wall St. Cheat Sheet
21-Mar-14 12:48PM  Tableau, Vertex, Wynn Setting Up Follow-On Buy Areas at Investor's Business Daily
08:44AM  Valeant Risks Dilution as Debt Threatens Rating: Canada Credit at Bloomberg
20-Mar-14 06:36PM  Tableau, Vertex, Wynn Setting Up Follow-On Buy Areas at Investor's Business Daily
06:31PM  Is Now a Good Time to Sell Anacor Pharmaceuticals, Inc.? at Motley Fool
06:21PM  Fund Strategists See Rosy Prognosis For Biotechs Stocks Like Biogen at Investor's Business Daily
06:01PM  Gentherm, Kors Setting Up in Tight Formations at Investor's Business Daily
09:24AM  Buy the Next McDonald's? 3 Prospects at Motley Fool
05:55AM  Riding Valeant's Momentum With Insiders at Seeking Alpha
18-Mar-14 05:21PM  Leaders Finding Support As Market Takes A Breather at Investor's Business Daily
16-Mar-14 04:15PM  3 Prescription Drugs You Didn't Know Come From Marijuana at Motley Fool
12-Mar-14 07:01PM  Three Leading Growth Names Pull Back To Key Support Level Optionetics
07:01PM  Three Leading Growth Names Pull Back To Key Support Level at Investor's Business Daily
07:01PM  Three Leading Growth Names Pull Back To Key Support Level
02:01PM  Can Valeant Continue This Growth? at Motley Fool
09:33AM  Greenberg: What You May Have Missed at TheStreet
10-Mar-14 11:23AM  How High Can Constellation Software Fly? at Motley Fool
08:35AM  Anacor names Vince Ippolito as Chief Commercial Officer at theflyonthewall.com
08:35AM  Anacor names Vince Ippolito as Chief Commercial Officer
07-Mar-14 05:49PM  Highflying Drug, Biotech Stocks Take Rare Drubbing Optionetics
05:49PM  Highflying Drug, Biotech Stocks Take Rare Drubbing at Investor's Business Daily
05:49PM  Highflying Drug, Biotech Stocks Take Rare Drubbing
04:28PM  Nasdaq Lags As Stock Market Closes Lower Optionetics
04:28PM  Nasdaq Lags As Stock Market Closes Lower at Investor's Business Daily
04:28PM  Nasdaq Lags As Stock Market Closes Lower
03:33PM  Early Gains Fade; E-House Breaks Out But Biotechs Stumble Optionetics
03:33PM  Early Gains Fade; E-House Breaks Out But Biotechs Stumble at Investor's Business Daily
03:33PM  Early Gains Fade; E-House Breaks Out But Biotechs Stumble
10:51AM  Why Did Valeant's Shares Plunge Yesterday? at Motley Fool
10:51AM  After Bagging Tesla Shares At $180, Savvy Value Pro Picks Three Other Stocks As Potential Huge Winners at Forbes
12:53AM  Why Chanos And Grant Are Wrong On Valeant at Seeking Alpha
06-Mar-14 01:04PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Financials EDGAR Online Financials
01:00PM  Insider Trading Alert - BIIB, VRX And AME Traded By Insiders at TheStreet
05-Mar-14 08:37AM  Russia actions could disrupt specialty pharmaceutical sales, says Susquehanna at theflyonthewall.com
04-Mar-14 06:31PM  Can Allergan's Growth Continue? at Motley Fool
05:13PM  Drugmakers Actavis, Biogen, Valeant Hold Near Highs at Investor's Business Daily
11:32AM  Teva Returns to Roots After Outside CEO Faces Nuthouse at Bloomberg
09:00AM  QLT Narrows Loss in Q4 Zacks
02-Mar-14 12:47PM  Greenberg: Buffett Tells Investors to Get Real About EBITDA at TheStreet
28-Feb-14 04:05PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-K, Annual Report EDGAR Online
12:02PM  3 Stocks Dragging In The Drugs Industry at TheStreet
11:28AM  This Stock Just Keeps on Rolling at Motley Fool
10:49AM  Valeant Beats Earnings & Revs in Q4 Zacks
27-Feb-14 06:00PM  Harness outsized gains with Cramer stock strategy at CNBC
05:38PM  Valeant Q4 Profit Tops; Takeover Plans Key Investor's Business Daily
03:10PM  Valeant Pharmaceuticals International Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
01:58PM  Stock leaders flex muscles at MarketWatch
12:07PM  Midday movers: PepsiCo, Sotheby's, eBay & More at CNBC
11:57AM  Stocks Regain Footing; Baidu Breaks Out at Investor's Business Daily
10:57AM  Valeant Q4 Earnings Beat Street; Stock Hits High at Investor's Business Daily
08:59AM  Stock Futures Slightly Lower; Best Buy, JC Penney Jump Higher at Investor's Business Daily
06:18AM  Valeant Pharmaceuticals swings to profit Reuters
06:17AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financ EDGAR Online
06:02AM  Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results CNW Group
06:00AM  Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results PR Newswire
25-Feb-14 11:02AM  Teva rises after analyst raises price target at theflyonthewall.com
24-Feb-14 06:24PM  Gilead Builds Rare Ascending Base at Investor's Business Daily
09:05AM  Moody's: Peak for Canadian spec-grade debt maturities moves to 2018 at Moody's
22-Feb-14 08:02AM  Valeant, Jazz Among IBD 50 Stocks Earnings This Week at Investor's Business Daily
21-Feb-14 06:46PM  Akorn, WuXi PharmaTech Clear Buy Points, Pace IBD 50 at Investor's Business Daily
03:30PM  Raptor Soars on Positive RP103 Data Zacks
20-Feb-14 06:28PM  Akorn, Several Other Leading Stocks Showing Promise at Investor's Business Daily
01:23PM  Stocks Tack On More Gains; Facebook Cuts Losses at Investor's Business Daily
07:26AM  Syneron Medical adds two directors to Board theflyonthewall.com
19-Feb-14 06:07PM  Medicals Among Top 20 Groups, Retailers Near Bottom at Investor's Business Daily
02:45PM  Top-Ranked Forest Labs Soars on Buyout News Zacks
18-Feb-14 05:38PM  Actavis, Forest Labs In Biggest Merger In Specialty Pharma Investor's Business Daily
03:00PM  Forest buyout may not spell the end of dealmaking for Actavis at MarketWatch
02:41PM  Actavis Deal May Become the Standard for Drug Deals at New York Times
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM
Weldon RyanEVP, Company Group ChairmanFeb 11Option Exercise0.0011,0000103,823Feb 12 04:43 PM
Stolz Brian M.EVP, Administration & CHCOFeb 11Option Exercise0.0014,700069,783Feb 12 04:08 PM
Schiller Howard BradleyEVP, CFOFeb 11Option Exercise0.0090,0000312,704Feb 12 03:51 PM
Kornwasser LaizerEVP, Company Group ChairmanFeb 11Option Exercise0.0045,000073,390Feb 12 03:34 PM
Provencio Norma AnnDirectorFeb 03Sale136.235,000681,158147,206Feb 04 06:15 PM
Weldon RyanEVP, Company Group ChairmanJan 24Option Exercise0.0019,0000101,539Jan 28 05:09 PM
Mirovsky PavelPresident of Valeant EuropeJan 24Option Exercise0.0010,000010,000Jan 28 05:00 PM
Kornwasser LaizerEVP, Company Group ChairmanJan 24Buy132.152,536335,12828,390Jan 28 04:51 PM
Stolz Brian M.EVP, Administration and CHCOJan 20Option Exercise0.0045,000077,939Jan 22 04:55 PM